Press releases
- Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
- Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
- Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
- Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
- Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
- Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024
- Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial
- Silence Therapeutics Announces Oversubscribed $120 Million Private Placement
More ▼
Key statistics
On Friday, Silence Therapeutics PLC (SLN:NMQ) closed at 21.99, -20.67% below its 52-week high of 27.72, set on Mar 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 21.68 |
---|---|
High | 22.57 |
Low | 21.07 |
Bid | 20.63 |
Offer | 23.40 |
Previous close | 21.30 |
Average volume | 161.60k |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼